Korro Bio Inc. provided an update on its RNA editing pipeline, highlighting interim data from the Phase 1/2a REWRITE study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD). The study showed generation of functional M-AAT protein and a tolerable safety profile consistent with lipid nanoparticle infusion effects. However, projected levels of functional protein were not reached after a single administration, and differences in pharmacokinetics were observed between healthy volunteers and AATD patients. The company announced a strategic shift to GalNAc-conjugated delivery for AATD with a development candidate expected in the first half of 2026. Korro Bio also nominated KRRO-121, a GalNAc-conjugated construct targeting hyperammonemia and broader urea cycle disorders, with regulatory filing planned for the second half of 2026. The company reported cash, cash equivalents, and marketable securities totaling $102.5 million as of September 30, 2025, supporting operations into the second half of 2027. You can access the full presentation through the link below.